Blogroll
Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Patent Opposition Database
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
-
Recent Posts
- Medical R&D Convention Derailed: Implications for the Global Health System
- Trans-Pacific Partnership undermines health system
- The Supreme Court Reveals its Ignorance of Genetics
- DIPP to send proposal to PMO on review of pharma FDI policy
- SUPREME COURT INVALIDATES PATENTS ON BREAST AND OVARIAN CANCER GENES
Categories
Category Archives: Indian Patent Law
Novartis: stop strangling the supply of affordable medicines from India
Source: Stop AIDS Campaign 19 September 2012 AIDS activists from across the UK staged a murder mystery inspired protest today outside the gates of a UK Novartis plant, demanding the Swiss pharmaceutical giant drops a court case which campaigners say … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d)
Tagged India, Novartis, United Kingdom
Leave a comment
Video: India’s drug-patent rules
As pharmaceutical giants Novartis and Bayer challenge India’s drug-patent rules, The Economist’s correspondents discuss the potential implications for health care in the developing world.
‘We can offer better drug access to developing countries’
Source: The Times of India Crest Edition 15 September 2012 DG Shah, secretary general of the Indian Pharmaceutical Alliance, has taken up the cudgels on behalf of domestic generic companies. He tells TOI-Crest that if the government wins the battle … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d), TRIPS flexibilities
Tagged Glivec, India, Novartis
Leave a comment
India: Balancing Public And Private Interests In The Intellectual Property Regime
Published on 18 September 2012 @ 2:03 pm By Patralekha Chatterjee for Intellectual Property Watch NEW DELHI – In this month, there have been two court orders in India that underscore the complexities underlying the country’s intellectual property regime. … Continue reading
Showdown for Big Pharma in India’s highest court
Source: Reutors MUMBAI/LONDON | Mon Aug 20, 2012 4:43am EDT (Reuters) – India’s highest court will hear final arguments starting this week in a landmark case over drug patents that could change the rules for the country’s healthcare sector and potentially curb … Continue reading
Posted in access to medicines, Indian Patent Law, IP Rights, Sec 3 (d)
Tagged Bayer, Glivec, Novartis, Paul Herrling
Leave a comment
From outlier to trendsetter
Source: Canadian Medical Association Journal July 18, 2012 The world’s brand-name drug makers have long viewed India as their problem child for delaying compliance with international property rights law while serving as the developing world’s pharmacy for generic drugs. … Continue reading
Activists from around the world gather in Cape Town and rally against Novartis attack on the ‘pharmacy of the developing world
Cape Town, 11 July 2012 /– Health activists, academics, medical doctors, government representatives, and lawyers today held a rally protesting the drug company Novartis’ court case against the Indian government, warning that the case could have a devastating impact on access to affordable medicines. … Continue reading
Rally by South African Groups against Novartis case against Indian Government
South African health activists, academics, medical doctors, government representatives, and lawyers will gather in Cape Town to rally against the legal case by the drug company Novartis against the government of India. The outcome of the case will have far-reaching … Continue reading
Novartis Case hearing in Supreme Court postponed again to 22 August 2012
final arguments in the Indian Supreme Court case of Novartis vs. Government of India has been re-scheduled for 22 August 2012. The case was due to start next Tuesday, 10 July. The postponement is due to a request from lawyers … Continue reading
Posted in Indian Patent Law, Novartis Case, Sec 3 (d)
Leave a comment
Big Pharma in legal battles for monopoly prices in India
Source: The Conversation Hans Lofgren 5 June 2012 Two large multinational pharmaceutical companies are fighting for patents and monopoly pricing in Indian courts. The outcomes of the cases – involving Novartis and Bayer – are likely to determine the country’s … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, TRIPS flexibilities
Tagged Bayer, Cipla, European Union, India, Natco, Novartis
Leave a comment
